BR9708401A - Vetores de vìrus de para-varìola - Google Patents

Vetores de vìrus de para-varìola

Info

Publication number
BR9708401A
BR9708401A BR9708401-8A BR9708401A BR9708401A BR 9708401 A BR9708401 A BR 9708401A BR 9708401 A BR9708401 A BR 9708401A BR 9708401 A BR9708401 A BR 9708401A
Authority
BR
Brazil
Prior art keywords
para
virus vectors
smallpox virus
encode
exogenous dna
Prior art date
Application number
BR9708401-8A
Other languages
English (en)
Inventor
Anthony John Robinson
David James Lyttle
Original Assignee
Univ Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Otago filed Critical Univ Otago
Publication of BR9708401A publication Critical patent/BR9708401A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4355—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from cestodes
    • C07K14/43554—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from cestodes from Taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Patente de Invenção: <B>"VETORES DE VìRUS DE PARA-VARìOLA"<D>. A invenção é dirigida a vetores de vírus de para-varíola. São especificamente providos os vetores de vírus orf contendo DNA exógeno. O DNA exógeno pode codificar um peptídeo heterólogo ou polipeptídeo do qual se deseja a expressão, ou pode codificar um antígeno capaz de induzir uma resposta imune. A capacidade para expressar antígenos torna estes vetores apropriados para uso em vacinas.
BR9708401-8A 1996-03-29 1997-03-27 Vetores de vìrus de para-varìola BR9708401A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ28628496 1996-03-29
PCT/NZ1997/000040 WO1997037031A1 (en) 1996-03-29 1997-03-27 Parapoxvirus vectors

Publications (1)

Publication Number Publication Date
BR9708401A true BR9708401A (pt) 2000-01-04

Family

ID=19925703

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708401-8A BR9708401A (pt) 1996-03-29 1997-03-27 Vetores de vìrus de para-varìola

Country Status (11)

Country Link
US (1) US20030013076A1 (pt)
EP (1) EP0904393A4 (pt)
JP (1) JP2000507449A (pt)
KR (1) KR20000005120A (pt)
CN (1) CN1217751A (pt)
AU (1) AU2182697A (pt)
BR (1) BR9708401A (pt)
CA (1) CA2250041A1 (pt)
HU (1) HUP9902438A3 (pt)
IL (1) IL126349A0 (pt)
WO (1) WO1997037031A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
WO2000025805A1 (en) * 1998-11-02 2000-05-11 Ludwig Institute For Cancer Research Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
DE10122451A1 (de) * 2000-07-11 2002-04-04 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
EP1303286B1 (de) * 2000-07-11 2006-04-26 Bayer HealthCare AG Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
US6723329B2 (en) * 2001-12-07 2004-04-20 Board Of Regents, The University Of Texas System Use of parapox B2L protein to modify immune responses to administered antigens
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP4311732B2 (ja) * 2004-04-13 2009-08-12 株式会社リコー 光ピックアップ装置及び光ディスク装置
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
CN104878043B (zh) * 2015-06-01 2017-12-05 石河子大学 羊口疮病毒毒力基因vir缺失突变株及其制备方法和应用
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
WO2017165366A1 (en) * 2016-03-21 2017-09-28 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
CN107299087B (zh) * 2016-04-15 2020-11-06 金宇保灵生物药品有限公司 用传代细胞系制备羊口疮病毒的方法
CN107287149B (zh) * 2017-05-09 2020-12-29 杨凌博德越生物科技有限公司 一种用于羊口疮病毒增殖的永久细胞系及其建立方法
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM710194A0 (en) * 1994-07-26 1994-08-18 Commonwealth Scientific And Industrial Research Organisation Virus vector
AU718141B2 (en) * 1996-02-28 2000-04-06 Bayer Healthcare Ag Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines

Also Published As

Publication number Publication date
JP2000507449A (ja) 2000-06-20
EP0904393A1 (en) 1999-03-31
AU2182697A (en) 1997-10-22
HUP9902438A2 (hu) 1999-11-29
IL126349A0 (en) 1999-05-09
KR20000005120A (ko) 2000-01-25
CA2250041A1 (en) 1997-10-09
EP0904393A4 (en) 1999-09-08
US20030013076A1 (en) 2003-01-16
CN1217751A (zh) 1999-05-26
HUP9902438A3 (en) 2000-03-28
WO1997037031A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
EP0904393A4 (en) PARAPOXVIRUS VECTORS
AR006999A1 (es) Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.
BR9711123A (pt) Quimeras de leucotoxina-gnrh
DE58906121D1 (de) Rekombinantes Vaccinia-Virus MVA.
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
ATE115187T1 (de) Poxvirus-vektoren.
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
EA200100425A1 (ru) Новые способы терапевтической вакцинации
BR9812139A (pt) Vacina
BR0015137A (pt) Peptìdeos antigênicos de neisseria
FI950665A0 (fi) Melanoomaan liittyvä antigeeninen polypeptidi, sen epitooppeja ja melanoomarokotteita
WO1995029193A3 (en) Melanoma antigens
KR910016343A (ko) 사람 파필로마바이러스(hpv) 16 단백질의 혈청반응성 에피토프
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
ATE175119T1 (de) Vakzine gegen immunodefizienz-virus der katze (kiv)
DK0990703T3 (da) Nyt polypeptid, DNA, som koder herfor, samt anvendelse heraf
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
AR009365A1 (es) Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno
DK0638316T3 (da) Rekombinante adenovirusvacciner
ATE126274T1 (de) Rekombinanter impfstoff gegen marek&#39;s krankheit.
ATE266090T1 (de) Gegen mumps impfstoff, das ein virus des jeryl- lynn stammes enthält
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
ATE122096T1 (de) Von babesia abgeleitete antigene und polypeptide (12d3-antigen).

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAYER AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO DE: UNIVERSITY OF OTAGO